Form 8-K - Current report:
SEC Accession No. 0001193125-25-039260
Filing Date
2025-02-27
Accepted
2025-02-27 16:16:59
Documents
15
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d909955d8k.htm   iXBRL 8-K 24501
2 EX-99.1 d909955dex991.htm EX-99.1 52028
6 GRAPHIC g909955g0227134825710.jpg GRAPHIC 2117
  Complete submission text file 0001193125-25-039260.txt   210251

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA etnb-20250227.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE etnb-20250227_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE etnb-20250227_pre.xml EX-101.PRE 11258
17 EXTRACTED XBRL INSTANCE DOCUMENT d909955d8k_htm.xml XML 3634
Mailing Address 655 MONTGOMERY STREET SUITE 1500 SAN FRANCISCO CA 94111
Business Address 655 MONTGOMERY STREET SUITE 1500 SAN FRANCISCO CA 94111 (415) 432-9270
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39122 | Film No.: 25679061
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)